Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
10/2010
10/05/2010US7807689 such as 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile, used for the treatment of breast cancer and non-insulin depepndent diabetes
10/05/2010US7807688 corticotropin releasing factor receptor antagonists such as 8-(N-butyl-N-(2-butynyl)amino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, used for the treatment of nervous system, psychological, eating, sleep, and gastrointestinal disorders
10/05/2010US7807682 Pyridyl cyanoguanidine compounds
10/05/2010US7807659 5-Fluoro-4-oxo-3-[1-(substituted-carbonyl)-2-piperidinecarboxamido]-pentanoic acid derivatives such as [3S/R (2S)]-5-Fluoro-4-oxo-3-[1-(2-phenyl-thiazole-4-carbonyl)-2-piperidinecarboxamido]-pentanoic acid, used for the treatment of bone disorders, inflammatory, autoimmune and degenerative diseases
10/05/2010US7807658 Administering an optionally substituted 3-aminopropylphosphinic acid (3-amino-2-fluoropropyl)phosphinic acid, 3-amino-2-oxopropyl)phosphinic acid); irritable bowel syndrome
10/05/2010US7807656 Pharmaceutical applications of hyaluronic acid preparations
10/05/2010US7807430 Polypeptide of 250-419 contiguous amino acids of SEQ ID NO:1, where tyrosine 216 is phosphorylated and the polypeptide will crystallize; biological activity consisting of binding a GSK3 inhibitor and kinase activity; antidiabetic agents; Alzeimer's disease; antiinflammation agents; biological screening
10/05/2010US7807170 Modulating an immune response in a subject by administering an effective amount of a lymphocyte differentiation factor; antiinflammatory agents
10/05/2010US7807167 using an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin; treatment of multiple sclerosis or inflammatory disease of the gastrointestinal tract
10/05/2010US7807142 comprising interleukin-2 (IL-2); using an amino acid base sufficient to decrease aggregate formation of the polypeptide during storage of the composition, and a buffering agent ; mixture with amino acid and buffer
10/05/2010CA2393297C Polyhydroxystilbenes as antipsoriatic agents and protein kinase inhibitors
10/05/2010CA2370784C Endodontic fibers and methods of use therefor
10/05/2010CA2367138C Anti-inflammatory uses of manzamines
09/2010
09/30/2010WO2010111527A1 Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
09/30/2010WO2010111240A2 Methods for treating inflammatory arthritis
09/30/2010WO2010111178A2 Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
09/30/2010WO2010110479A1 Activator for peroxisome proliferator-activated receptor
09/30/2010WO2010109687A1 Coral-derived therapeutic agent for inflammations and allergic diseases
09/30/2010WO2010109329A1 Furopyrimidinedione derivatives as trpa1 modulators
09/30/2010WO2010109328A1 Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
09/30/2010WO2010109287A1 Fused pyrimidine-dione derivatives as trpa1 modulators
09/30/2010WO2010108651A1 Substituted spiro-amide compounds
09/30/2010WO2010089510A3 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
09/30/2010WO2010065491A3 Methods of treating inflammatory disorders
09/30/2010WO2010056919A3 Eflornithine prodrugs, conjugates and salts, and methods of use thereof
09/30/2010WO2010046273A3 Pyrimidinyl pyridone inhibitors of jnk
09/30/2010WO2010034011A9 Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release
09/30/2010WO2010003022A8 Isoindolone derivatives as mek kinase inhibitors and methods of use
09/30/2010WO2009127949A8 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
09/30/2010US20100249243 Novel beta-hydroxyketones and beta-alkoxyketones with estrogenic activity
09/30/2010US20100249241 N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
09/30/2010US20100249238 Pharmaceutical compositions comprising semicarbazones and thiosemicarbazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms of inflammation
09/30/2010US20100249237 Non-Steroidal Anti-Inflammatory Drug Dosing Regimen
09/30/2010US20100249223 New use for cannabinoid-containing plant extracts
09/30/2010US20100249222 Methods of treating skin with aromatic skin-active ingredients
09/30/2010US20100249216 Method for the production of a cell and/or tissue and/or disease phase specific medicament
09/30/2010US20100249206 Modified lysine-mimetic compounds
09/30/2010US20100249203 Compounds that inhibit trpv1 and uses thereof
09/30/2010US20100249200 Novel Compounds 569
09/30/2010US20100249198 (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
09/30/2010US20100249195 Pyridylphenyl compounds for inflammation and immune-related uses
09/30/2010US20100249189 Nitric oxide donor compounds
09/30/2010US20100249183 Therapeutic use of n-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives
09/30/2010US20100249174 Ccr1 antagonists and methods of use therefor
09/30/2010US20100249168 Compounds and Formulations Suitable for Radical Scavenging
09/30/2010US20100249154 Compositions useful for treating disorders related to trpa1
09/30/2010US20100249149 Inhibitors of Protein Kinases
09/30/2010US20100249144 Substituted piperazines as cb1 antagonists
09/30/2010US20100249129 Compounds as cannabinoid receptor ligands
09/30/2010US20100249128 Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
09/30/2010US20100249118 Compounds and methods for kinase modulation, and indications therefor
09/30/2010US20100249114 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
09/30/2010US20100249102 Heterotricyclic Metalloprotease Inhibitors
09/30/2010US20100249101 Malonamide derivatives with antithrombotic activity
09/30/2010US20100249100 Quinazolines useful as modulators of ion channels
09/30/2010US20100249095 Substituted Spiro-amide Compounds
09/30/2010US20100249092 Heteroaryl compounds and uses thereof
09/30/2010US20100249091 Amide Compounds Useful in Therapy
09/30/2010US20100249087 Compounds as cannabinoid receptor ligands
09/30/2010US20100249086 Compounds As Cannabinoid Receptor Ligands
09/30/2010US20100249085 Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
09/30/2010US20100249079 Analogues of cilostazol
09/30/2010US20100249078 Tetracyclic inhibitors of fatty acid amide hydrolase
09/30/2010US20100249074 Benzyl-cycloalkyl sphingosine 1-phosphate receptor modulators
09/30/2010US20100249071 Modulators of S1P and Methods of Making And Using
09/30/2010US20100249069 S1p3 receptor inhibitors for treating pain
09/30/2010US20100249066 Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
09/30/2010US20100249057 Trehalose compound and pharmaceutical comprising the compound
09/30/2010US20100249034 Gfralpha3 and its uses
09/30/2010US20100249019 Use of a peptide as a therapeutic agent
09/30/2010US20100249016 Metal-binding compounds and uses therefor
09/30/2010US20100247694 Composition and method for treament of inflamation and infections of the outer ear canal, nose and paranasal sinuses
09/30/2010US20100247668 Polymer-agent conjugates, particles, compositions, and related methods of use
09/30/2010US20100247645 Pharmaceutical combination of aliskiren and valsartan
09/30/2010US20100247617 Transdermal Administration Of (2S)-(4E)-N-Methyl-5-(3-(5-Isopropoxypyridin)yl)-4-Penten-2-Amine
09/30/2010US20100247591 Skin Treatment Compositions Containing Copper-Pigment Complexes
09/30/2010US20100247587 Pigmentation-regulating compounds
09/30/2010US20100247577 Tr1 cells, mesenchymal stem cells and uses thereof
09/30/2010US20100247545 Antibodies to m-csf
09/30/2010US20100247544 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms
09/30/2010US20100247534 Fused heterocyclic compounds as inhibitors of potassium channel function
09/30/2010US20100247526 Anti-NKG2A Antibodies and Uses Thereof
09/30/2010US20100247523 Subtypes of humanized antibody against interleuken-6 receptor
09/30/2010US20100247511 Methods and compositions for activated protein c with reduced anticoagulant properties
09/30/2010US20100247509 Fusion Proteins
09/30/2010US20100247483 Therapeutic agent composition and method of use
09/30/2010US20100247482 Tight junction modulator peptides for enhanced mucosal delivery of therapeutic compounds
09/30/2010US20100247468 Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds
09/30/2010US20100247463 N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
09/30/2010US20100247453 Composition and method of treating a sore throat
09/30/2010US20100247439 Dendritic nano-antioxidants
09/30/2010CA2756536A1 Thienopyrimidinedione derivatives as trpa1 modulators
09/30/2010CA2756535A1 Furopyrimidinedione derivatives as trpa1 modulators
09/30/2010CA2756534A1 Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
09/30/2010CA2756532A1 Substituted spiro-amide compounds
09/30/2010CA2756518A1 Fused pyrimidinedione derivatives as trpa1 modulators
09/29/2010EP2233498A1 Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same
09/29/2010EP2233486A1 Azaindoles
09/29/2010EP2233483A1 Indole or Benzimidazole derivatives as IkB-kinase modulators and intermediates in their preparation.
09/29/2010EP2233138A1 Tape preparation comprising etodolac in ionic liquid form
1 ... 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 ... 1272